CN102666540A - 用于治疗乙酰胆碱受体相关疾病的稠合吖嗪衍生物 - Google Patents

用于治疗乙酰胆碱受体相关疾病的稠合吖嗪衍生物 Download PDF

Info

Publication number
CN102666540A
CN102666540A CN2010800465507A CN201080046550A CN102666540A CN 102666540 A CN102666540 A CN 102666540A CN 2010800465507 A CN2010800465507 A CN 2010800465507A CN 201080046550 A CN201080046550 A CN 201080046550A CN 102666540 A CN102666540 A CN 102666540A
Authority
CN
China
Prior art keywords
methyl
diazabicyclo
esi
nonan
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800465507A
Other languages
English (en)
Chinese (zh)
Inventor
P·D·拉特克利夫
T·R·克拉森
F·杰里米亚
J·K·F·麦克利恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organic Agricultural Biological Sciences Holland Co ltd
Merck Sharp and Dohme BV
Original Assignee
Organon NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Organon NV filed Critical Organon NV
Publication of CN102666540A publication Critical patent/CN102666540A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN2010800465507A 2009-10-13 2010-10-11 用于治疗乙酰胆碱受体相关疾病的稠合吖嗪衍生物 Pending CN102666540A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US25110109P 2009-10-13 2009-10-13
EP09172872.5 2009-10-13
EP09172872 2009-10-13
US61/251101 2009-10-13
PCT/EP2010/065160 WO2011045258A1 (en) 2009-10-13 2010-10-11 Condensed azine - derivatives for the treatment of diseases related to the acetylcholine receptor

Publications (1)

Publication Number Publication Date
CN102666540A true CN102666540A (zh) 2012-09-12

Family

ID=42040651

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800465507A Pending CN102666540A (zh) 2009-10-13 2010-10-11 用于治疗乙酰胆碱受体相关疾病的稠合吖嗪衍生物

Country Status (12)

Country Link
US (1) US8841289B2 (enExample)
EP (1) EP2488520B1 (enExample)
JP (1) JP2013507417A (enExample)
KR (1) KR20120100913A (enExample)
CN (1) CN102666540A (enExample)
AU (1) AU2010305825A1 (enExample)
BR (1) BR112012008518A2 (enExample)
CA (1) CA2776835A1 (enExample)
IN (1) IN2012DN02968A (enExample)
MX (1) MX2012004289A (enExample)
RU (1) RU2012119488A (enExample)
WO (1) WO2011045258A1 (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106146410A (zh) * 2015-04-03 2016-11-23 中南大学 6-氨基-4(3h)-喹唑啉酮衍生物及其合成方法和用途
WO2016192667A1 (zh) * 2015-06-03 2016-12-08 北京大学 一种噻唑并嘧啶酮化合物及其制备方法和应用
CN112424198A (zh) * 2018-07-13 2021-02-26 吉瑞工厂 噻二嗪衍生物
CN112469707A (zh) * 2018-06-27 2021-03-09 利伯纳生物科学株式会社 脊髓性肌萎缩症的预防剂或治疗剂
CN112898290A (zh) * 2021-01-29 2021-06-04 中南大学 异噁唑甲酰胺基-4(3h)-喹唑啉酮衍生物及其合成方法和用途
WO2025176185A1 (zh) * 2024-02-23 2025-08-28 海思科医药集团股份有限公司 一种braf抑制剂的制备方法

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2843383A1 (en) 2011-07-29 2013-02-07 Taisho Pharmaceutical Co., Ltd. Amidine compound or salt thereof
MX346147B (es) 2012-03-07 2017-03-09 Inst Of Cancer Research: Royal Cancer Hospital (The) Compuestos de 3-aril-5-substituido-isoquinolin-1-ona y su uso terapeutico.
US20150164858A1 (en) * 2012-05-22 2015-06-18 King Abdullah University Of Science And Technology Combination comprising parthenolide for use in the treatment of alzheimer's disease and other neurodegenerative disorders
JP6456392B2 (ja) 2013-09-11 2019-01-23 インスティチュート オブ キャンサー リサーチ：ロイヤル キャンサー ホスピタル ３−アリール−５−置換イソキノリン−１−オン化合物及びその治療的使用
EP3191459A1 (en) 2014-09-05 2017-07-19 AbbVie Deutschland GmbH & Co. KG Fused heterocyclic or carbocyclic compounds carrying a substituted cycloaliphatic radical and use thereof for treating vasopressin-related diseases
WO2016100184A1 (en) 2014-12-16 2016-06-23 Forum Pharmaceuticals, Inc. Geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors
MA41291A (fr) 2014-12-30 2017-11-07 Forma Therapeutics Inc Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer
TWI698436B (zh) 2014-12-30 2020-07-11 美商佛瑪治療公司 作為泛素特異性蛋白酶７抑制劑之吡咯并及吡唑并嘧啶
EP3253738A1 (en) 2015-02-05 2017-12-13 Forma Therapeutics, Inc. Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors
US9932351B2 (en) 2015-02-05 2018-04-03 Forma Therapeutics, Inc. Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors
WO2016126935A1 (en) 2015-02-05 2016-08-11 Forma Therapeutics, Inc. Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors
WO2016201096A1 (en) 2015-06-10 2016-12-15 Forum Pharmaceuticals, Inc. Aminobenzisoxazole compounds as agonists of a7-nicotinic acetylcholine receptors
WO2017027600A1 (en) 2015-08-12 2017-02-16 Forum Pharmaceuticals, Inc. GEMINAL SUBSTITUTED AMINOBENZISOXAZOLE COMPOUNDS AS AGONISTS OF α7-NICOTINIC ACETYLCHOLINE RECEPTORS
EP4006038A1 (en) 2015-12-09 2022-06-01 Cadent Therapeutics, Inc. Thienopyrimidinone nmda receptor modulators and uses thereof
HRP20201522T1 (hr) * 2015-12-09 2020-12-11 Cadent Therapeutics, Inc. Heteroaromatski nmda receptor modulatori i njihove uporabe
EP3558318B1 (en) 2016-12-22 2023-12-20 Novartis AG Nmda receptor modulators and uses thereof
JP7633676B2 (ja) 2018-07-26 2025-02-20 ドメイン・セラピューティクス 置換キナゾリノン誘導体、及びｍＧｌｕＲ４のポジティブアロステリック調節剤としてのその使用
CU24647B1 (es) 2018-08-03 2023-02-13 Cadent Therapeutics Inc Moduladores del receptor nmda heteroaromático
WO2021198188A1 (en) 2020-03-30 2021-10-07 Enyo Pharma Quinazolinone derivatives and uses thereof for treating a cancer
WO2021198191A1 (en) 2020-03-30 2021-10-07 Enyo Pharma Quinazolinone derivatives and uses thereof for treating a cancer
US12180193B2 (en) 2020-08-28 2024-12-31 Arvinas Operations, Inc. Accelerating fibrosarcoma protein degrading compounds and associated methods of use
US11957759B1 (en) 2022-09-07 2024-04-16 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003062235A1 (en) * 2002-01-17 2003-07-31 Eli Lilly And Company Modulators of acetylcholine receptors
WO2008033764A2 (en) * 2006-09-11 2008-03-20 N.V. Organon Quinazolinone and isoquinolinone acetamide derivatives
WO2008077555A2 (en) * 2006-12-27 2008-07-03 Sanofi-Aventis Substituted isoquinolines and their use as rho-kinase inhibitors
WO2009017236A1 (ja) * 2007-08-01 2009-02-05 Taisho Pharmaceutical Co., Ltd. ピリドピリミジン－４－オン誘導体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0000540D0 (sv) 2000-02-18 2000-02-18 Astrazeneca Ab New compounds
JP2005504730A (ja) * 2001-04-20 2005-02-17 バーテックス　ファーマシューティカルズ　インコーポレイテッド Ｇｓｋ−３インヒビターとして有用な組成物
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
TW200536830A (en) * 2004-02-06 2005-11-16 Chugai Pharmaceutical Co Ltd 1-(2H)-isoquinolone derivative
UA93882C2 (ru) * 2005-07-26 2011-03-25 Санофи-Авентис Пиперидинил-замещенные производные изохинолона kak ингибиторы rho-киназы
JP2011503145A (ja) * 2007-11-14 2011-01-27 ノイロサーチ アクティーゼルスカブ 新規な１，４−ジアザ−ビシクロ［３．２．２］ノニルピリミジン誘導体及びその医学的使用
EP2249455A1 (en) 2008-02-29 2010-11-10 Techno Core International Co., Ltd. Charging device and quality judging device of pack cell

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003062235A1 (en) * 2002-01-17 2003-07-31 Eli Lilly And Company Modulators of acetylcholine receptors
WO2008033764A2 (en) * 2006-09-11 2008-03-20 N.V. Organon Quinazolinone and isoquinolinone acetamide derivatives
WO2008077555A2 (en) * 2006-12-27 2008-07-03 Sanofi-Aventis Substituted isoquinolines and their use as rho-kinase inhibitors
WO2009017236A1 (ja) * 2007-08-01 2009-02-05 Taisho Pharmaceutical Co., Ltd. ピリドピリミジン－４－オン誘導体

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106146410A (zh) * 2015-04-03 2016-11-23 中南大学 6-氨基-4(3h)-喹唑啉酮衍生物及其合成方法和用途
CN106146410B (zh) * 2015-04-03 2018-10-12 中南大学 6-氨基-4(3h)-喹唑啉酮衍生物及其合成方法和用途
WO2016192667A1 (zh) * 2015-06-03 2016-12-08 北京大学 一种噻唑并嘧啶酮化合物及其制备方法和应用
CN106279211A (zh) * 2015-06-03 2017-01-04 北京大学 一种噻唑并嘧啶酮化合物及其制备方法和应用
US10450326B2 (en) 2015-06-03 2019-10-22 Peking University Thiazolopyrimidinone compounds and preparation methods and use thereof
CN106279211B (zh) * 2015-06-03 2020-09-15 北京大学 一种噻唑并嘧啶酮化合物及其制备方法和应用
US12012410B2 (en) 2018-06-27 2024-06-18 Reborna Biosciences, Inc. Substituted pyrazolo[1,5-a]pyrazines for spinal muscular atrophy
CN112469707A (zh) * 2018-06-27 2021-03-09 利伯纳生物科学株式会社 脊髓性肌萎缩症的预防剂或治疗剂
CN112469707B (zh) * 2018-06-27 2024-06-21 利伯纳生物科学株式会社 脊髓性肌萎缩症的预防剂或治疗剂
CN112424198A (zh) * 2018-07-13 2021-02-26 吉瑞工厂 噻二嗪衍生物
US12194050B2 (en) 2018-07-13 2025-01-14 Richter Gedeon Nyrt. Thiadiazine derivatives
CN112898290A (zh) * 2021-01-29 2021-06-04 中南大学 异噁唑甲酰胺基-4(3h)-喹唑啉酮衍生物及其合成方法和用途
WO2025176185A1 (zh) * 2024-02-23 2025-08-28 海思科医药集团股份有限公司 一种braf抑制剂的制备方法

Also Published As

Publication number Publication date
WO2011045258A1 (en) 2011-04-21
CA2776835A1 (en) 2011-04-21
KR20120100913A (ko) 2012-09-12
BR112012008518A2 (pt) 2016-04-05
MX2012004289A (es) 2012-06-12
JP2013507417A (ja) 2013-03-04
US8841289B2 (en) 2014-09-23
AU2010305825A1 (en) 2012-04-19
EP2488520A1 (en) 2012-08-22
IN2012DN02968A (enExample) 2015-07-31
RU2012119488A (ru) 2013-11-20
US20120208796A1 (en) 2012-08-16
EP2488520B1 (en) 2015-09-02

Similar Documents

Publication Publication Date Title
CN102666540A (zh) 用于治疗乙酰胆碱受体相关疾病的稠合吖嗪衍生物
CN116635371B (zh) 一种作为sos1抑制剂的多环哒嗪酮类衍生物、其制备方法及用途
EP2802577B1 (en) Triazolyl-substituted pyridyl compounds useful as kinase inhibitors
AU2019291935A1 (en) Inhibitors of cyclin-dependent kinases
WO2014060112A1 (en) Pyrazolo[4,3-d]pyrimidines as kinase inhibitors
CA2716410A1 (en) 1-heterocyclyl-1,5-dihydro-pyrazolo[3,4-d] pyrimidin-4-one derivatives and their use as pde9a inhibitors
JP2018524338A (ja) 複素環化合物
CN101679371A (zh) 作为腺苷受体拮抗剂的取代的嘧啶
JP2008531723A (ja) フタラジン、アザ及びジアザフタラジン化合物並びに使用方法
NZ584430A (en) Quinazolinedione derivatives, preparation thereof and therapeutic uses thereof
CN115003667B (zh) Tyk-2抑制剂
JP2006520766A (ja) 置換された８−パーフルオロアルキル−６，７，８，９−テトラヒドロピリミド［１，２−ａ］ピリミジン−４−オン誘導体
EP1957492B1 (en) Substituted bicyclic pyrimidone derivatives
JP2022547729A (ja) 自己免疫疾患を治療するためのピペリジニルアミン化合物
RS63661B1 (sr) Piridopirimidini kao inhibitori histaminskog h4-receptora
JP6977038B2 (ja) Ｇｓｋ−３阻害剤
WO2009043884A1 (en) Azabicyclo [3. 1. 0] hexyl derivatives as modulators of dopamine d3 receptors
JP2006519813A (ja) 置換された２−（ジアザ−ビシクロ−アルキル）−ピリミドン誘導体
WO2024261329A1 (en) Heteroaryl-amine compounds and use thereof as hdac6 inhibitors
CA2716202A1 (en) Pyrrolo[2,3-d]pyrimidin-2-yl-amine derivatives as pkc-theta inhibitors
HK40046541B (en) Pyridopyrimidines as histamine h4-receptor inhibitors
HK40046541A (en) Pyridopyrimidines as histamine h4-receptor inhibitors
AU2006314136A1 (en) Substituted bicyclic pyrimidone derivatives
HK40011582A (en) Novel substituted pyrimidine compounds
HK1085742B (en) Substituted 2-(diaza-bicyclo-alkyl)-pyrimidone derivatives

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: ORGANON BIOSCIENCES NEDERLAND B. V.

Free format text: FORMER OWNER: MSD OUSI CO., LTD.

Effective date: 20130628

Owner name: MERCK SHARP + DOHME CORP.

Free format text: FORMER OWNER: ORGANON BIOSCIENCES NEDERLAND B. V.

Effective date: 20130628

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20130628

Address after: Haarlem

Applicant after: MERCK SHARP & DOHME B.V.

Address before: Holland

Applicant before: Organic agricultural biological sciences Holland Co.,Ltd.

Effective date of registration: 20130628

Address after: Holland

Applicant after: Organic agricultural biological sciences Holland Co.,Ltd.

Address before: Holland

Applicant before: N.V. Organon

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20120912